REGENERON PHARMACEUTICALS INC

NASDAQ: REGN (Regeneron Pharmaceuticals, Inc.)

Kemas kini terakhir: 03 Jan, 4:54PM

718.15

2.96 (0.41%)

  • 1H 0.41%
  • 5H 0.41%
  • 1B -0.93%
  • 6B -33.63%
  • Tahun Ke Tarikh 0.00%
  • 1T -23.38%
  • 5T 83.79%
Penutupan Terdahulu 715.19
Buka 716.07
Jumlah Dagangan 553,987
Purata Dagangan (3B) 817,548
Modal Pasaran 78,917,509,120
Harga / Pendapatan (P/E TTM) 17.77
Harga / Pendapatan (P/E Ke hadapan) 15.53
Harga / Jualan (P/S) 5.84
Harga / Buku (P/B) 2.63
Julat 52 Minggu
693.00 (-3%) — 1,211.20 (68%)
Tarikh Pendapatan 31 Jan 2025 - 4 Feb 2025
Margin Keuntungan 33.61%
Margin Operasi (TTM) 33.43%
EPS Cair (TTM) 40.40
Pertumbuhan Hasil Suku Tahunan (YOY) 10.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 33.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 9.22%
Nisbah Semasa (MRQ) 5.28
Aliran Tunai Operasi (OCF TTM) 4.25 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 2.25 B
Pulangan Atas Aset (ROA TTM) 7.41%
Pulangan Atas Ekuiti (ROE TTM) 17.17%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Regeneron Pharmaceuticals, Inc. Menurun Menurun

AISkor Stockmoo

0.9
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam -3.0
Volatiliti Harga 4.5
Purata Bergerak Teknikal 3.5
Osilator Teknikal -2.0
Purata 0.90

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
REGN 79 B - 17.77 2.63
VRTX 106 B - - 6.80
ARGX 40 B - - 9.21
GMAB 14 B - 22.15 3.08
BMRN 13 B - 41.19 2.35
TLX 5 B - 166.22 20.71

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 1.57%
% Dimiliki oleh Institusi 90.66%
Julat 52 Minggu
693.00 (-3%) — 1,211.20 (68%)
Julat Harga Sasaran
165.00 (-77%) — 1,215.00 (-99%)
Tinggi 1,215.00 (RBC Capital, 69.19%) Beli
Median 1,067.50 (48.65%)
Rendah 165.00 (Canaccord Genuity, -77.02%) Pegang
Purata 989.88 (37.84%)
Jumlah 12 Beli, 3 Pegang, 1 Jual
Harga Purata @ Panggilan 810.43
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Citigroup 14 Jan 2025 795.00 (10.70%) Pegang 696.88
14 Nov 2024 895.00 (24.63%) Pegang 782.51
Wells Fargo 10 Jan 2025 900.00 (25.32%) Beli 696.88
22 Oct 2024 1,050.00 (46.21%) Beli 962.34
Truist Securities 08 Jan 2025 1,004.00 (39.80%) Beli 733.59
01 Nov 2024 1,126.00 (56.79%) Beli 843.60
Bernstein 07 Jan 2025 1,070.00 (48.99%) Beli 730.30
Canaccord Genuity 17 Dec 2024 165.00 (-77.02%) Pegang 740.01
B of A Securities 10 Dec 2024 565.00 (-21.33%) Jual 778.50
Wolfe Research 15 Nov 2024 1,150.00 (60.13%) Beli 756.81
Oppenheimer 06 Nov 2024 1,000.00 (39.25%) Beli 816.65
BMO Capital 01 Nov 2024 1,190.00 (65.70%) Beli 843.60
Barclays 01 Nov 2024 1,065.00 (48.30%) Beli 843.60
23 Oct 2024 1,080.00 (50.39%) Beli 941.39
Morgan Stanley 01 Nov 2024 1,184.00 (64.87%) Beli 843.60
Piper Sandler 01 Nov 2024 1,195.00 (66.40%) Beli 843.60
RBC Capital 01 Nov 2024 1,215.00 (69.18%) Beli 843.60
25 Oct 2024 1,260.00 (75.45%) Beli 933.02
Evercore ISI Group 24 Oct 2024 1,175.00 (63.61%) Beli 928.90
JP Morgan 24 Oct 2024 1,150.00 (60.13%) Beli 928.90
Cantor Fitzgerald 23 Oct 2024 1,015.00 (41.34%) Pegang 941.39
Papar semua
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
SING GEORGE L 715.19 - 166 118,722
Jumlah Keseluruhan Kuantiti Bersih 166
Jumlah Keseluruhan Nilai Bersih ($) 118,722
Purata Pembelian Keseluruhan ($) 715.19
Purata Jualan Keseluruhan ($) -
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
SING GEORGE L Pengarah 02 Jan 2025 Diperolehi (+) 166 715.19 118,722
  • 3M
Tarikh Jenis Butiran
13 Jan 2025 Pengumuman Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
13 Jan 2025 Pengumuman Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
13 Jan 2025 Pengumuman Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
07 Jan 2025 Pengumuman Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
19 Dec 2024 Pengumuman Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
17 Dec 2024 Pengumuman EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
17 Dec 2024 Pengumuman Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
16 Dec 2024 Pengumuman Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
09 Dec 2024 Pengumuman Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
07 Dec 2024 Pengumuman Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
15 Nov 2024 Pengumuman Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
13 Nov 2024 Pengumuman Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
11 Nov 2024 Pengumuman Regeneron Announces Investor Conference Presentations
06 Nov 2024 Pengumuman Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
31 Oct 2024 Pengumuman Regeneron Reports Third Quarter 2024 Financial and Operating Results
24 Oct 2024 Pengumuman Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
18 Oct 2024 Pengumuman Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda